Dr. Oliver Reimann

Oliver played a pivotal role in co-founding Belyntic and advancing a groundbreaking peptide manufacturing technology. His responsibilities encompassed fundraising, technology establishment, implementation, CMC & supply and strategic alliance management. Serving as the co-founding managing director, he guided the company until its successful acquisition by Mesa Laboratories Inc. (NASDAQ: MLAB) in late 2022.

Motivated by his enthusiasm for crafting impactful molecules for pharmaceutical purposes, he persisted in his journey at Belyntic. He spearheaded the development of an innovative vaccine platform technology, with the intention of translating it into tangible drug candidates in the next phase.

Oliver completed his PhD in Organic Chemistry/Synthetic Biology from the Free University in 2016, immediately launching into the spin-out project for Belyntic thereafter.